Candel Therapeutics, Inc.(CADL)Stock Analysis
AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →13F Pro Quality Score
Not in ranked universe
Below size threshold
Below the main board's size threshold of $25M annual revenue or $100M total assets. This company reported $0.1M in revenue and is scored on the micro-cap board instead.
Financial data, filings, and institutional holdings below are still tracked in full — only the proprietary quality composite is unavailable for this name.
CADL Stock Analysis & AI Quality Score
Data updated 2026-07-26AI stock analysis and institutional research for Candel Therapeutics, Inc. (CADL), a Healthcare sector company. CADL is not currently included in 13F Pro's AI-ranked quality universe — below the main board's size threshold of $25m annual revenue or $100m total assets. this company reported $0.1m in revenue and is scored on the micro-cap board instead. Based on the latest XBRL financial filings (Q2 2026), Candel Therapeutics, Inc. reports net income of $-38.9M, free cash flow of $-17.3M. Top institutional holders of CADL by reported 13-F value include FMR, RTW INVESTMENTS, BlackRock, based on the most recent SEC filings. CADL trades on the Nasdaq exchange and files with the SEC under CIK 1841387. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate CADL daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Candel Therapeutics, Inc. directly from SEC EDGAR.
Net Income
Q2 2026
$-38.9M
Free Cash Flow
Q2 2026
$-17.3M
Revenue & Net Income
Earnings Per Share
Key Financials Over Time
Export Financial Table · ProRevenue
Net Income
+30.8% YoYOperating Income
-44.6% YoYEPS (Diluted)
+58.6% YoYTotal Assets
+17.2% YoYTotal Debt
-100.0% YoYOp. Cash Flow
-41.8% YoYFree Cash Flow
-43.9% YoY| Metric | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Revenue | — | — | — | $125.0K +0.0% | $125.0K +0.0% | $125.0K |
| Net Income | $-38.2M +30.8% | $-55.2M -45.4% | $-37.9M -101.9% | $-18.8M +48.0% | $-36.1M -104.3% | $-17.7M |
| Operating Income | $-48.3M -44.6% | $-33.4M +13.1% | $-38.4M -10.6% | $-34.7M -35.0% | $-25.7M -86.3% | $-13.8M |
| EPS (Diluted) | $-0.72 +58.6% | $-1.74 -32.8% | $-1.31 -101.5% | $-0.65 +66.0% | $-1.91 | — |
| Total Assets | $125.2M +17.2% | $106.9M +159.4% | $41.2M -47.0% | $77.7M -12.9% | $89.2M +133.0% | $38.3M |
| Total Debt | $0.00 -100.0% | $11.6M -43.3% | $20.5M | — | $560.0K +15.9% | $483.0K |
| Operating Cash Flow | $-38.3M -41.8% | $-27.0M +21.1% | $-34.2M -9.0% | $-31.4M -41.4% | $-22.2M -144.9% | $-9.1M |
| Free Cash Flow | $-38.9M -43.9% | $-27.0M +22.1% | $-34.7M -6.1% | $-32.7M -36.0% | $-24.1M -128.1% | $-10.5M |
Get alerted when CADL's score changes
Free account: watchlist tracking, the daily AI brief, and the AI screener.
Available Research
13F Pro tracks comprehensive data for Candel Therapeutics, Inc. including:
Top Institutional Holders of CADL
FMR LLC
$113.2M10,990,535 shRTW INVESTMENTS, LP
$66.1M6,422,018 shBlackRock, Inc.
$51.2M4,969,040 shSTATE STREET CORP
$36.6M3,549,823 shACORN CAPITAL ADVISORS, LLC
$36.0M3,497,948 shPortolan Capital Management, LLC
$36.0M3,490,398 shSaturn V Capital Management LP
$34.0M3,303,686 shVANGUARD CAPITAL MANAGEMENT LLC
$27.7M2,694,040 shGEODE CAPITAL MANAGEMENT, LLC
$16.2M1,571,021 shMILLENNIUM MANAGEMENT LLC
$11.3M1,093,905 sh
| Fund | Value | Shares |
|---|---|---|
| FMR LLC | $113.2M | 10,990,535 |
| RTW INVESTMENTS, LP | $66.1M | 6,422,018 |
| BlackRock, Inc. | $51.2M | 4,969,040 |
| STATE STREET CORP | $36.6M | 3,549,823 |
| ACORN CAPITAL ADVISORS, LLC | $36.0M | 3,497,948 |
| Portolan Capital Management, LLC | $36.0M | 3,490,398 |
| Saturn V Capital Management LP | $34.0M | 3,303,686 |
| VANGUARD CAPITAL MANAGEMENT LLC | $27.7M | 2,694,040 |
| GEODE CAPITAL MANAGEMENT, LLC | $16.2M | 1,571,021 |
| MILLENNIUM MANAGEMENT LLC | $11.3M | 1,093,905 |
More Healthcare Companies
View all Healthcare →Put CADL on your watchlist
Track score changes the day Candel Therapeutics, Inc. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.
Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).
Popular Research
Is CADL a good stock to buy?
13F Pro's AI-powered analysis of Candel Therapeutics, Inc. (CADL) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for CADL are available on the CADL stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing. CADL is classified as a small company.
Which hedge funds own CADL?
Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling CADL. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of Candel Therapeutics, Inc.'s investment landscape.